Abstract | OBJECTIVE: DESIGN: Randomised controlled trials (RCTs) evaluating the efficacy and safety of approved treatments for macular oedema secondary to BRVO were identified from an updated systematic review. SETTING: A Bayesian network meta-analysis of RCTs of treatments for macular oedema secondary to BRVO. INTERVENTIONS: OUTCOME MEASURES: Efficacy outcomes were mean change in best corrected visual acuity (Early Treatment Diabetic Retinopathy Study scale) and the percentage of patients gaining ≥ 15 letters. Safety outcome was the percentage of patients with increased intraocular pressure (IOP)/ ocular hypertension ( OH). RESULTS: CONCLUSIONS:
|
Authors | Stephane A Regnier, Michael Larsen, Vladimir Bezlyak, Felicity Allen |
Journal | BMJ open
(BMJ Open)
Vol. 5
Issue 6
Pg. e007527
(Jun 05 2015)
ISSN: 2044-6055 [Electronic] England |
PMID | 26048209
(Publication Type: Comparative Study, Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Copyright | Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. |
Chemical References |
- Recombinant Fusion Proteins
- aflibercept
- Dexamethasone
- Receptors, Vascular Endothelial Growth Factor
- Ranibizumab
|
Topics |
- Adult
- Dexamethasone
(administration & dosage, adverse effects)
- Humans
- Laser Coagulation
(adverse effects, methods)
- Macular Edema
(etiology, therapy)
- Randomized Controlled Trials as Topic
- Ranibizumab
(administration & dosage, adverse effects)
- Receptors, Vascular Endothelial Growth Factor
(administration & dosage, adverse effects)
- Recombinant Fusion Proteins
(administration & dosage, adverse effects)
- Retinal Vein Occlusion
(complications)
- Treatment Outcome
|